Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Insider Purchases $34,600.00 in Stock

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) insider William Benton Jones acquired 20,000 shares of the company’s stock in a transaction on Monday, May 6th. The shares were acquired at an average cost of $1.73 per share, for a total transaction of $34,600.00. Following the completion of the acquisition, the insider now owns 153,773 shares of the company’s stock, valued at $266,027.29. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Corvus Pharmaceuticals Trading Up 3.6 %

CRVS stock opened at $2.03 on Friday. Corvus Pharmaceuticals, Inc. has a 1-year low of $1.05 and a 1-year high of $4.19. The stock has a market cap of $99.55 million, a price-to-earnings ratio of -3.90 and a beta of 1.05. The company’s 50 day moving average is $1.77 and its 200 day moving average is $1.79.

Corvus Pharmaceuticals (NASDAQ:CRVS) last posted its quarterly earnings data on Tuesday, March 19th. The company reported ($0.14) earnings per share for the quarter, meeting the consensus estimate of ($0.14). As a group, sell-side analysts forecast that Corvus Pharmaceuticals, Inc. will post -0.47 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on CRVS. Cantor Fitzgerald reissued an “overweight” rating on shares of Corvus Pharmaceuticals in a report on Monday, April 1st. Mizuho reiterated a “neutral” rating and issued a $3.50 target price on shares of Corvus Pharmaceuticals in a research note on Wednesday, March 27th. Finally, Oppenheimer boosted their price target on shares of Corvus Pharmaceuticals from $7.00 to $8.00 and gave the company an “outperform” rating in a research report on Tuesday.

Hedge Funds Weigh In On Corvus Pharmaceuticals

A hedge fund recently raised its stake in Corvus Pharmaceuticals stock. Towerview LLC lifted its holdings in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) by 67.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 342,478 shares of the company’s stock after purchasing an additional 137,478 shares during the period. Corvus Pharmaceuticals comprises about 0.3% of Towerview LLC’s investment portfolio, making the stock its 18th biggest position. Towerview LLC owned 0.70% of Corvus Pharmaceuticals worth $500,000 as of its most recent SEC filing. 46.64% of the stock is currently owned by institutional investors and hedge funds.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.